Departments and Services | For Patients | Research & Trials | Education | Find a Doctor


Search:
Division of Infectious Disease
 
    
Division of Infections Disease
 
Home
Fellowship Program
Clinical Programs
Penn CDC Prevention Epicenters Program
Clinical Trials
Penn CFAR
Botswana-UPenn Partnership
Seminars
Faculty
Adjunct Faculty
Administrative Contacts
Outpatient Clinics
News

Faculty

faculty photo

Jay R. Kostman, M.D.

Clinical Professor of Medicine
Health System Clinician, University of Pennsylvania Health System
Attending Physician , Penn Presbyterian Medical Center
Associate Director, Viral Hepatitis Center Perelman School of Medicine
Department: Medicine

Contact information
3910 Powelton Avenue
PPMC
Philadelphia, PA 19104
Office: 215-662-8693
Fax: 215-243-4658
Education:
B.A. (Chemistry)
Cornell University, 1980.
MD
Yale University, 1984.
Post-Graduate Training
Resident in Medicine, Temple University Hospital, Philadelphia, PA, 1984-1987.
Chief Resident in Medicine, Temple University Hospital, Philadelphia, PA , 1987-1988.
Fellow in Infectious Diseases, Temple University Hospital, Philadelphia, PA , 1988-1991.
Certifications
American Board of Internal Medicine, 1987.
Subspecialty of Infectious Diseases, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ: Shift in Monocyte Apoptosis with Increasing Viral Load and Change in Apoptosis-related ISG/Bcl2-family Gene Expression in Chronic HIV-1 Infected Subjects. Journal of Virology Oct 2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang Yu-Xiao, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V: Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. Journal of Hepatology 61(2): 210-8, Aug 2014.

Kozak I, Vaidya V, Van Natta ML, Pak JW, May KP, Thorne JE: The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Investigative Ophthalmology & Visual Science 55(7): 4304-12, Jul 2014.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD: Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. Journal of the American Heart Association 3(3): e000844, Jun 2014.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KBF, Herlim M, Yang Y-X, Hennessy S, Kostman JR, Leonard MB, Localio R, Lo Re V: Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007. Annals of Epidemiology 24(6): 418-23, Jun 2014.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang K-M, Lo Re V: Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. Journal of Viral Hepatitis 21(4): 288-96, Apr 2014.

Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of Internal Medicine 160(6): 369-79, Mar 2014.

Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ: A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers. PloS one 9(7): e103209, 2014.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD: Factors associated with D-dimer levels in HIV-infected individuals. PloS one 9(3): e90978, 2014.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ: Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen. J Inf Dis 208(2): 363, Jul 2013.

back to top
Last updated: 11/11/2014
The Trustees of the University of Pennsylvania